{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=9", "query": { "intervention": "Placebo Intravenous", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 2346, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T17:07:25.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01934361", "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma Multiforme" ], "interventions": [ { "name": "buparlisib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "lomustine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-02-28", "completion_date": "2016-07-07", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934361" }, { "nct_id": "NCT07581002", "title": "A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Pivekimab Sunirine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Matching Placebo for PVEK", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2026-06-30", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 6, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07581002" }, { "nct_id": "NCT03139279", "title": "Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colonoscopy" ], "interventions": [ { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "Saline placebo", "type": "OTHER" }, { "name": "Propofol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "State University of New York - Downstate Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 122, "start_date": "2017-05-05", "completion_date": "2018-07-19", "has_results": true, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139279" }, { "nct_id": "NCT02989194", "title": "Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "VIS410 low dose", "type": "DRUG" }, { "name": "VIS410 high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Visterra, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2017-01-06", "completion_date": "2017-10-27", "has_results": true, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Homestead", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02989194" }, { "nct_id": "NCT02709512", "title": "Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "ADI-PEG 20 plus Pem Platinum", "type": "DRUG" }, { "name": "Placebo plus Pem Platinum", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2017-08-01", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709512" }, { "nct_id": "NCT00246012", "title": "A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Intetumumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2005-05", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2013-08-19", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246012" }, { "nct_id": "NCT02168595", "title": "Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Subjects" ], "interventions": [ { "name": "GMI-1271", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlycoMimetics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "19 Years to 60 Years" }, "enrollment_count": 28, "start_date": "2014-06", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168595" }, { "nct_id": "NCT04262167", "title": "Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease" ], "interventions": [ { "name": "Lung Spheroid Stem Cells 100 million", "type": "BIOLOGICAL" }, { "name": "Lung Spheroid Stem Cells 200 million", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2020-10-22", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262167" }, { "nct_id": "NCT00228904", "title": "Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetic Neuropathy" ], "interventions": [ { "name": "Placebo", "type": "PROCEDURE" }, { "name": "Pulsatile IV insulin delivery (humalog, humulin, novolog)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Florida Atlantic University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "20 Years to 90 Years" }, "enrollment_count": 0, "start_date": "2005-02", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2016-08-10", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 1, "location_summary": "Boca Raton, Florida", "locations": [ { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00228904" }, { "nct_id": "NCT04356352", "title": "Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Injection Site Irritation", "Pain" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" }, { "name": "Esmolol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 33, "start_date": "2020-09-09", "completion_date": "2023-08-25", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-10T17:07:25.496Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356352" } ] }